Tom Stargardt

4.3k total citations
115 papers, 2.2k citations indexed

About

Tom Stargardt is a scholar working on Economics and Econometrics, General Health Professions and Pharmacology. According to data from OpenAlex, Tom Stargardt has authored 115 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Economics and Econometrics, 33 papers in General Health Professions and 13 papers in Pharmacology. Recurrent topics in Tom Stargardt's work include Health Systems, Economic Evaluations, Quality of Life (46 papers), Pharmaceutical Economics and Policy (30 papers) and Healthcare Policy and Management (16 papers). Tom Stargardt is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (46 papers), Pharmaceutical Economics and Policy (30 papers) and Healthcare Policy and Management (16 papers). Tom Stargardt collaborates with scholars based in Germany, United States and Netherlands. Tom Stargardt's co-authors include Jonas Schreyögg, Reinhard Busse, Oliver Tiemann, Iryna Sabat, Sebastian Neumann‐Böhme, Pedro Pita Barros, Carl Rudolf Blankart, Katharina Elisabeth Fischer, Charles M. Alexander and Sotiris Vandoros and has published in prestigious journals such as PLoS ONE, Social Science & Medicine and Journal of Affective Disorders.

In The Last Decade

Tom Stargardt

110 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Stargardt Germany	28	884	528	225	187	181	115	2.2k
Suzy Paisley United Kingdom	28	884 1.0×	564 1.1×	184 0.8×	188 1.0×	320 1.8×	75	3.2k
Justin W. Timbie United States	20	527 0.6×	531 1.0×	249 1.1×	119 0.6×	252 1.4×	64	1.7k
Brooke Nickel Australia	25	340 0.4×	667 1.3×	162 0.7×	192 1.0×	218 1.2×	94	2.1k
James Zhang United States	28	558 0.6×	540 1.0×	159 0.7×	76 0.4×	204 1.1×	113	2.7k
Roberto Cardarelli United States	21	252 0.3×	257 0.5×	278 1.2×	100 0.5×	149 0.8×	63	2.1k
Ilmo Keskimäki Finland	29	421 0.5×	867 1.6×	89 0.4×	243 1.3×	516 2.9×	162	2.9k
Mary E. Slaughter United States	20	244 0.3×	478 0.9×	121 0.5×	228 1.2×	190 1.0×	62	2.2k
Maria Lucia Specchia Italy	25	361 0.4×	681 1.3×	132 0.6×	181 1.0×	136 0.8×	116	2.0k
Leah L. Zullig United States	35	1.0k 1.2×	1.1k 2.0×	430 1.9×	154 0.8×	286 1.6×	224	4.2k
Roxanne E. Jensen United States	27	374 0.4×	718 1.4×	355 1.6×	139 0.7×	243 1.3×	71	2.9k

Countries citing papers authored by Tom Stargardt

Since Specialization

Citations

This map shows the geographic impact of Tom Stargardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Stargardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Stargardt more than expected).

Fields of papers citing papers by Tom Stargardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Stargardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Stargardt. The network helps show where Tom Stargardt may publish in the future.

Co-authorship network of co-authors of Tom Stargardt

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Stargardt. A scholar is included among the top collaborators of Tom Stargardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Stargardt. Tom Stargardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stargardt, Tom, et al.. (2024). To merge or not to merge? The impact of mergers and acquisitions on corporate success in the pharmaceutical industry. Managerial and Decision Economics. 45(4). 2196–2209. 2 indexed citations

Bokemeyer, Bernd, Sandra Plachta‐Danielzik, Eugen I. Urzica, et al.. (2024). Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD_BIO‐ASSIST study). Alimentary Pharmacology & Therapeutics. 59(9). 1082–1095. 2 indexed citations

König, Hans‐Helmut, Sebastian Neumann‐Böhme, Iryna Sabat, et al.. (2023). Health-related quality of life in seven European countries throughout the course of the COVID-19 pandemic: evidence from the European COvid Survey (ECOS). Quality of Life Research. 32(6). 1631–1644. 14 indexed citations

Bokemeyer, Bernd, et al.. (2023). Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease. The European Journal of Health Economics. 25(3). 539–548. 4 indexed citations

Sabat, Iryna, Sebastian Neumann‐Böhme, Saskia Knies, et al.. (2022). Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries. Health and Quality of Life Outcomes. 20(1). 129–129. 3 indexed citations

Stargardt, Tom, et al.. (2022). Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades. BMC Health Services Research. 22(1). 1457–1457. 11 indexed citations

Malyar, Nasser, et al.. (2022). Cost-utility analysis of early versus delayed endovascular intervention in critical limb-threatening ischemia patients with rest pain. Journal of Vascular Surgery. 77(1). 299–308.e2. 4 indexed citations

Hajek, André, Sebastian Neumann‐Böhme, Iryna Sabat, et al.. (2022). Depression and anxiety in later COVID-19 waves across Europe: New evidence from the European COvid Survey (ECOS). Psychiatry Research. 317. 114902–114902. 20 indexed citations

Jensen, Morten Lind, et al.. (2020). Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study. JMIR mhealth and uhealth. 8(11). e22212–e22212. 47 indexed citations

10.

Rech, Jürgen, et al.. (2020). Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE. 15(1). e0226754–e0226754. 10 indexed citations

11.

Hofer, Florian, Hans‐Ulrich Kauczor, & Tom Stargardt. (2018). Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung Cancer. 124. 189–198. 47 indexed citations

12.

Helms, Thomas M., Sigmund Silber, Andreas Schäfer, et al.. (2016). Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern. Herzschrittmachertherapie + Elektrophysiologie. 27(3). 295–306. 3 indexed citations

13.

Blank, Sally E., et al.. (2014). Forecasting Outpatient Pharmaceutical Expenditure for Cancer Treatment in Germany. Value in Health. 17(7). A621–A621. 1 indexed citations

14.

Schreyögg, Jonas & Tom Stargardt. (2012). Gesundheitsökonomische Evaluation auf Grundlage von GKV-Routinedaten. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 55(5). 668–676. 10 indexed citations

15.

Stargardt, Tom, et al.. (2011). Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching. The European Journal of Health Economics. 13(5). 549–560. 18 indexed citations

16.

Stargardt, Tom, Paraskevi Mavrogiorgou, Christian A. Gericke, & Georg Juckel. (2011). Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. Psychopharmacology. 216(4). 579–587. 4 indexed citations

17.

Schreyögg, Jonas, Tom Stargardt, & Oliver Tiemann. (2010). Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matching. Health Economics. 20(1). 85–100. 38 indexed citations

18.

Schreyögg, Jonas & Tom Stargardt. (2010). The Trade‐Off between Costs and Outcomes: The Case of Acute Myocardial Infarction. Health Services Research. 45(6p1). 1585–1601. 39 indexed citations

19.

Buck, Andreas K., Ken Herrmann, Tom Stargardt, et al.. (2010). Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. Journal of Nuclear Medicine Technology. 38(1). 6–17. 86 indexed citations

20.

Stargardt, Tom, Jonas Schreyögg, & Reinhard Busse. (2007). Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany. Health Policy. 84(1). 30–38. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact